Developing next generation non-replicative HSV-1 vectors for sustainable and more precise gene therapies
Join this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts will outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have potential to expand future applications for gene therapy.
Streamlining the path from lab to market with 3D bioprinting
By Dr Vidmantas Šakalys (Vital3D), Ellen Capon (Drug Target Review)
Women in STEM with Dr Petra Dieterich
By Dr Petra Dieterich (Abenza), Taylor Mixides (Drug Target Review)
Women in Stem with Katherine Tran
By Katherine Tran (SCIEX), Taylor Mixides (Drug Target Review)
Bile acids and the microbiome: revolutionising disease approaches
By Ellen Capon (Drug Target Review)
Beyond the lab: artificial intelligence
Amidst the transformative era of artificial intelligence in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision and effectiveness in identifying drug targets.
Streamlining the path from lab to market with 3D bioprinting
By Dr Vidmantas Šakalys (Vital3D), Ellen Capon (Drug Target Review)
Women in STEM with Dr Petra Dieterich
By Dr Petra Dieterich (Abenza), Taylor Mixides (Drug Target Review)
Women in Stem with Katherine Tran
By Katherine Tran (SCIEX), Taylor Mixides (Drug Target Review)